Solidseq CGP (>550 Genes Panel + TMB + MSI) Test
About Solidseq CGP (>550 Genes Panel + TMB + MSI) Test
| Field | Value |
|---|---|
| Also Known As | Comprehensive Genomic Profiling (CGP), Tumour Genomic Panel, Solidseq Tumour Profiling, NGS Cancer Panel |
| Sample Type | FFPE Tumour Tissue Block (formalin-fixed, paraffin-embedded tissue from biopsy or surgical excision) |
| Fasting Required | No |
| Report Time | 30 days |
| Recommended For | Adults with advanced or metastatic cancers; patients being considered for targeted therapy or immunotherapy; clinical trial candidates requiring genomic profiling |
| Price | Starting at ₹84,000 |
What Is a Solidseq CGP (>550 Genes Panel + TMB + MSI) Test?
The Solidseq CGP (>550 genes panel + TMB + MSI) test is a next-generation sequencing (NGS)-based cancer profiling test. It analyses over 550 cancer-related genes from a tumour tissue sample in a single run. The test also measures two key biomarkers, tumour mutational burden (TMB) and microsatellite instability (MSI), which help predict how a patient may respond to immunotherapy. It is also known as comprehensive genomic profiling (CGP), tumour genomic panel, Solidseq tumour profiling, or NGS cancer panel.
What Does a Solidseq CGP (>550 Genes Panel + TMB + MSI) Test Measure?
The Solidseq CGP (>550 genes panel + TMB + MSI) test analyses genetic changes across a broad panel of cancer-related genes, alongside key tumour biomarkers. Below are the key biomarkers and gene categories assessed:
| Biomarker | What It Measures |
|---|---|
| TMB (Tumour Mutational Burden) | Total number of mutations per megabase of the tumour genome. TMB-High (10 or more mutations per megabase) may predict better response to immunotherapy |
| MSI (Microsatellite Instability) | Reported as MSS (Microsatellite Stable), MSI-Low, or MSI-High. MSI-High indicates defects in the mismatch repair system and may predict response to immune checkpoint inhibitors |
The table below lists each gene category, the genes tested, and the purpose of testing:
| Gene Category | Genes Included | Purpose of Testing |
|---|---|---|
| Oncogenes | EGFR, KRAS, BRAF, ALK, RET, MET, NRAS, PIK3CA, ERBB2, ROS1, NTRK1, NTRK2, NTRK3, AKT1, AKT2, AKT3, ARAF, RAF1, MAP2K1, MAP2K2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, PDGFRA, PDGFRB, JAK1, JAK2, JAK3, MYC, MYCN, MYCL, MDM2, MDM4, FLT1, KDR, MTOR, SRC, RPS6KB1, RPS6KB2 | Identify targetable mutations for approved or trial-based targeted therapies |
| Tumour Suppressor Genes | TP53, RB1, APC, PTEN, CDKN2A, CDKN2B, CDKN2C, BRCA1, BRCA2, NF1, NF2, SMAD2, SMAD3, SMAD4, STK11, LATS1, LATS2, FAT1, FBXW7, VHL region genes, TP73, TP53BP1 | Assess loss-of-function mutations affecting cell cycle control and DNA repair |
| DNA Repair Genes | BRCA1, BRCA2, ATM, ATR, PALB2, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FANCM, MLH1, MSH2, MSH3, MSH6, PMS1, PMS2, POLE, POLQ, MUTYH, BLM, RECQL4, MRE11, NBN, RAD50, ERCC2, ERCC3, ERCC4, ERCC5, RRM1, DPYD | Identify candidates for PARP inhibitors; assess homologous recombination deficiency |
| Cell Cycle Regulators | CDK2, CDK4, CDK6, CDK7, CDK8, CDK12, CCND1, CCND2, CCND3, CCNE1, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, RB1, E2F3 | Assess alterations affecting control of cell division |
| Signalling Pathway Genes | JAK1, JAK2, JAK3, STAT1, STAT3, STAT5B, MTOR, FGFR1, FGFR2, FGFR3, FGFR4, KIT, PDGFRA, PDGFRB, IGF1R, EPHA2, EPHA3, DDR1, DDR2, CSF1R, APLNR, ADGRA2, LTK, LYN, SYK, BTK, PTPN11, PTPRD, PTPRO, PTPRS, PTPRT, PAK1, PAK3, PAK7, RAC1, RHOA, RHEB, RASA1, RIT1, SOS1, MAP3K1, MAP2K4, MAPK1, CRKL, RICTOR, RPTOR, RPS6KA4, PIK3CA, PIK3CB, PIK3CD, PIK3R1, PIK3R2, PLCG1, AKT1, AKT2, AKT3, KEAP1, NFE2L2 | Identify alterations in growth signalling pathways relevant to targeted treatment |
| Chromatin Remodelling and Epigenetic Genes | ARID1A, ARID1B, ARID2, ARID5B, SMARCA4, SMARCB1, KMT2A, KMT2B, KMT2C, KMT2D, EZH2, DNMT1, DNMT3A, DNMT3B, DOT1L, EP300, CREBBP, CHD2, CHD4, CHD8, PBRM1, BAP1, SETD2, ASXL1, ASXL2, KDM5C, KDM6A, MECOM, NSD1, NSD3, DAXX, ATRX, CENPA, H3F3A, H3F3B, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, HIST1H3J, HIST2H3C, HIST1H1C | Assess epigenetic regulation alterations in tumour biology |
| Immune-Related Genes | CD274 (PD-L1), PDCD1LG2, CTLA4, HLA-A, HLA-B, HLA-C, B2M, JAK1, JAK2, CD22, CD38, CD44, CD58, CD74, CD79A, CD79B, BIRC3, CARD11, CIITA, IDO1, IDO2, IFNGR1, IFNGR2, IL6ST, IRF1, NLRC5, RFX5, RFXAP, TAP1, TAP2, TAPBP, SOCS1, BCL2, CRBN, PIAS3, PIAS4 | Evaluate immune checkpoint and antigen presentation pathways; predict immunotherapy response |
| Transcription Factors and Other Genes | ABL1, ABL2, ABR, ABRAXAS1, ACVR1, ACVR1B, ACVR2A, AJUBA, AKAP9, ALOX12B, ALOX15B, AMER1, ANKRD11, ANKRD26, ARFRP1, ARHGAP26, ARHGAP35, AXIN1, AXIN2, BARD1, BCOR, BRIP1, BTG1, BTG2, CASP8, CASR, CBFB, CBL, CBLB, CDC73, CDH1, CFTR, CIC, CKS1B, COL17A1, CPA1, CRLF2, CSAD, CSNK1A1, CTCF, CTNNB1, CUL3, CUL4A, CUL4B, CUX1, CYLD, DCUN1D1, DDX3X, DDX5, DEFB134, DHX9, DICER1, DIS3, DIS3L2, DLX1, DNAJB1, EED, EGFL7, EIF4A2, ELF3, ELOC, ERG, ESR1, ETV1, ETV4, ETV5, ETV6, FAS, FGF19, FOXA1, FOXA2, FOXL2, FOXO1, FOXP1, FUBP1, GATA3, GATA6, GNA11, GNA13, GNAQ, GNAS, GPS2, HGF, HIF1A, HNF1A, HRAS, IDH1, IDH2, IDHD1, JUN, KLF4, LAMP1, LMO1, LRP1B, LZTR1, MAX, MCL1, MED12, MEN1, MGA, MGMT, MYB, MYH9, NAB2, NCOA2, NCOR1, NFKB2, NFKBIA, NKX2, NKX3, NOTCH1, NOTCH2, NOTCH3, NOTCH4, NPM1, NRG1, NUP93, NUTM1, P2RY8, PAX5, PCBP1, PHF6, PSIP1, PSMA1, PSMB5, PSMD1, PSMG2, PTCH1, PTK2, QKI, QSER1, RAD21, RBM10, REL, REST, RFX5, RFXAP, RNF43, RPL22, RPL5, RSPO2, RUNX1, SERPINB3, SERPINB4, SETBP1, SF3B1, SLC34A2, SMC1A, SMC3, SMG1, SMO, SPOP, SPEN, SRSF2, STAG1, STAG2AXL, TAF1, TAF3, TBL1XR1, TBX3, TCF12, TCF7L2, TERT, TET2, TGFBR2, TGFBRN, TMPRSS2, TMPRSS2 | Covers a broad range of additional cancer-associated genes for complete tumour characterisation |
Why Is a Solidseq CGP (>550 Genes Panel + TMB + MSI) Test Done?
This test is ordered by oncologists when a detailed molecular profile of a tumour is needed to guide treatment decisions. It covers a wide range of cancer types and clinical situations.
Common Symptoms and Indications That May Require This Test
The following clinical situations commonly prompt an oncologist to recommend the Solidseq CGP (>550 genes panel + TMB + MSI) test:
- Cancer that has progressed or recurred despite standard treatment
- Newly diagnosed advanced or metastatic cancer requiring targeted therapy evaluation
- Cancer of unknown primary origin where the site of origin is unclear
- Treatment resistance requiring alternative therapeutic options
- Evaluation for eligibility in clinical trials that require genomic profiling
- Suspected hereditary cancer syndrome based on personal or family history
- Multiple prior therapies with limited remaining standard options
Conditions This Test Can Help Detect
This test provides molecular guidance across a wide range of cancers. The following are common indications:
- Lung cancer (EGFR, ALK, ROS1, KRAS, BRAF, MET, RET, NTRK mutations or fusions)
- Breast cancer (BRCA1, BRCA2, PIK3CA, ERBB2 alterations)
- Colorectal cancer (KRAS, NRAS, BRAF mutations; MSI status)
- Ovarian cancer (BRCA1, BRCA2; homologous recombination deficiency)
- Pancreatic cancer (KRAS, BRCA1, BRCA2, PALB2)
- Melanoma (BRAF, NRAS mutations)
- Gastrointestinal stromal tumours (KIT, PDGFRA)
- Various solid tumours requiring complete molecular profiling for treatment decisions
How to Prepare and What to Expect
Because this test uses tumour tissue rather than a blood or urine sample, the preparation steps differ from routine laboratory tests. Your oncologist and the collection team will guide you through the process.
Do You Need to Fast?
No fasting is required. This test uses tumour tissue rather than blood or urine, so dietary restrictions do not apply. Always follow specific instructions provided by your doctor.
Practical Tips Before Your Test
Keep the following points in mind before submitting your tissue sample:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Inform your oncologist about all prior treatments, surgeries, and biopsies before the tissue is submitted
- Ensure the FFPE tissue block is from a biopsy taken no more than four months prior to testing; fresher samples produce better results
Step-by-Step Procedure
The Solidseq CGP (>550 genes panel + TMB + MSI) test procedure involves the following steps:
- Your oncologist or surgeon arranges a biopsy or surgical excision to collect tumour tissue from the affected site.
- The tissue sample is fixed in formalin and embedded in paraffin wax to create an FFPE tissue block, which preserves the genetic material.
- A pathologist reviews the tissue block to confirm that it contains sufficient tumour content and is of acceptable quality for sequencing.
- Genetic material (DNA and RNA) is extracted from the tumour tissue in the laboratory.
- The extracted material is processed using next-generation sequencing (NGS), which analyses all genes in the panel simultaneously along with TMB and MSI status.
- A bioinformatics team analyses the sequencing data and generates a detailed report, which is delivered within 30 days of sample submission.
Factors That Can Affect Accuracy
The following factors may reduce the reliability of results:
- Low tumour content in the tissue sample (less than 20% tumour cells)
- Poor tissue fixation technique or use of non-standard fixatives
- Aged or degraded tissue blocks with reduced DNA integrity
- Insufficient quantity of extracted DNA or RNA
- Prior chemotherapy or radiation, which may alter the tumour's mutational profile
Understanding Your Solidseq CGP (>550 Genes Panel + TMB + MSI) Test Results
Results from this test are not reported as simple normal or abnormal values. Instead, the report provides a detailed list of detected genomic alterations classified by their clinical significance. Your oncologist will review these findings alongside your full clinical picture. The table below shows a summary of key findings:
| Parameter | Result Category | Clinical Significance |
|---|---|---|
| TMB (Tumour Mutational Burden) | TMB-Low (less than 10 mutations per megabase) | Standard treatment options; lower likelihood of response to immune checkpoint inhibitor therapy based on TMB alone. |
| TMB (Tumour Mutational Burden) | TMB-High (10 or more mutations per megabase) | May indicate increased likelihood of response to immune checkpoint inhibitor therapy depending on tumour type and clinical context. |
| MSI Status | MSS / MSI-Low | Proficient mismatch repair; immunotherapy based on MSI status alone is generally not indicated. |
| MSI Status | MSI-High | Deficient mismatch repair; associated with better response to immunotherapy and may suggest Lynch syndrome. |
| Gene Variants | Pathogenic / Likely Pathogenic | Clinically actionable; may support targeted therapy selection or clinical trial eligibility. |
| Gene Variants | VUS (Variant of Uncertain Significance) | Clinical significance is uncertain; not used for treatment decisions. |
| Gene Variants | Benign / Likely Benign | Not clinically significant; no therapeutic action required. |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain circumstances may influence how results are interpreted:
- Prior chemotherapy or radiation may alter the tumour's mutational profile; a post-treatment biopsy may show different findings compared to a pre-treatment sample.
- Tumour heterogeneity means that different areas of the same tumour, or different metastatic sites, may carry distinct mutations not fully captured by a single biopsy.
- Archival tissue blocks may have lower DNA integrity, which can reduce sequencing success rates compared to prospectively collected samples.
How to Maintain Healthy Levels
This test characterises an existing tumour rather than measuring a health parameter that can be improved by lifestyle changes. The following are general recommendations after receiving results:
- Follow your oncologist's guidance on treatment based on the molecular findings in your report.
- If hereditary variants such as BRCA1 or BRCA2 mutations are detected, discuss genetic counselling with your doctor.
- Consider informing close family members if germline mutations with familial implications are identified, as they may benefit from genetic testing.
Lupin Diagnostics Solidseq CGP (>550 Genes Panel + TMB + MSI) Test Price
The Solidseq CGP (>550 genes panel + TMB + MSI) test cost at Lupin Diagnostics starts at ₹84,000. This test requires a visit to a Lupin Diagnostics centre or submission of an FFPE tissue block through your treating hospital; home collection is not available for this test. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 84000 |
| Pune | 84000 |
| Bangalore | 84000 |
| Chennai | 84000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for the Solidseq CGP (>550 genes panel + TMB + MSI) test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample submission, or coordinate with your treating hospital to send the FFPE tissue block directly.
- Receive your report via email or WhatsApp within 30 days of sample submission.
Frequently Asked Questions
The Solidseq CGP (>550 genes panel + TMB + MSI) test is a next-generation sequencing-based cancer profiling test. It analyses more than 550 cancer-related genes in a single run along with TMB and MSI status. The results help oncologists identify targeted therapies or immunotherapies that may be suitable for a specific patient's tumour.
This test is recommended for patients with advanced or metastatic cancers where standard treatments are insufficient or no longer effective. It is also ordered for patients being evaluated for targeted therapy, immunotherapy, or clinical trial eligibility. Your oncologist will advise whether this test is appropriate for your situation.
The test requires a formalin-fixed, paraffin-embedded (FFPE) tumour tissue block. This is obtained through a biopsy or surgical excision performed by a qualified healthcare professional.
At Lupin Diagnostics, the report is typically delivered within 30 days of the laboratory receiving the tissue sample. The test results are delivered directly via email or WhatsApp.
This test is performed on tumour tissue and primarily identifies somatic (tumour-specific) mutations. However, certain variants detected, such as those in BRCA1, BRCA2, or other known hereditary cancer genes, may suggest a germline (inherited) mutation. If this is suspected, your oncologist will refer you for dedicated germline testing and genetic counselling.
No, Solidseq CGP (>550 genes panel + TMB + MSI) test home collection is not available. This test requires tumour tissue obtained through a biopsy or surgery, which must be performed by qualified healthcare professionals in a clinical setting.
Solidseq CGP (>550 Genes Panel + TMB + MSI) Test
